Small-molecule antagonists of the immune checkpoint pathways: concept to clinic

Future Medicinal ChemistryVol. 9, No. 12 EditorialSmall-molecule antagonists of the immune checkpoint pathways: concept to clinicPottayil G Sasikumar & Murali RamachandraPottayil G Sasikumar Aurigene Discovery Technologies Limited, Bangalore, India & Murali Ramachandra*Author for correspondence: E-mail Address: murali_r@aurigene.com Aurigene Discovery Technologies Limited, Bangalore, IndiaPublished Online:3 Aug 2017https://doi.org/10.4155/fmc-2017-0107AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antagonistcheckpoint inhibitorimmunomodulatorimmuno-oncologyimmunotherapyorally bioavailablePD-1 pathwayprotein–protein interactionsmall moleculeVISTAReferences1 Greil R, Hutterer E, Hartmann TN, Pleyer L. Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation. Cell Commun. Signal. 15, 5–16 (2017).Crossref, Medline, Google Scholar2 Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26(12), 2375–2391 (2015).Crossref, Medline, CAS, Google Scholar3 Sharpe A, Butte M, Oyama S: WO/2011/082400 (2011).Google Scholar4 Chang H-N, Liu B-Y, Qi Y-K et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 54, 11760–11764 (2015).Crossref, Medline, CAS, Google Scholar5 Miller MM, Mapelli C, Allen MP et al.: WO/2014/151634 (2014).Google Scholar6 Chupak LS, Zheng X: WO/2015/034820 (2015).Google Scholar7 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).Crossref, Medline, CAS, Google Scholar8 Spaller M, Noelle R, Ceeraz S et al.: WO/2015/109340 (2015).Google Scholar9 Sasikumar PGN, Ramachandra M: US8907053 B2 (2014).Google Scholar10 Sasikumar PGN, Ramachandra M: US9422339 B2 (2016).Crossref, Google Scholar11 Sasikumar PGN, Ramachandra M, Naremaddepalli SSS: WO/2015/033303 (2015).Google Scholar12 Sasikumar P, Shrimali R, Adurthi S et al. A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events. J. Immunother. Cancer 1, O24 (2013).Crossref, Google Scholar13 Fenwick C, Pellaton C, Farina A et al. Identification of novel antagonistic anti-PD-1 antibodies that are non-blocking of the PD-1/PD-L1 interaction. J. Clin. Oncol. 34, A3072 (2016).Crossref, Google Scholar14 Scheuplein F, Ranganath S, McQuade T et al. Abstract B30: Discovery and functional characterization of novel anti-PD-1 antibodies using ex vivo cell-based assays, single-cell immunoprofiling, and in vivo studies in humanized mice. Cancer Res. 76, B30 (2016).Crossref, Medline, Google Scholar15 Lin DY-W, Tanaka Y, Iwasaki M et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011–3016 (2008).Crossref, Medline, CAS, Google Scholar16 Zak KM, Kitel R, Przetocka S et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23, 2341–2348 (2015).Crossref, Medline, CAS, Google Scholar17 Zak KM, Grudnik P, Guzik K et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7, 30323–30335 (2016).Crossref, Medline, Google Scholar18 Sasikumar PGN, Ramachandra M, Naremaddepalli SSS: WO/2015/033299 (2015).Google Scholar19 Sasikumar PGN, Ramachandra M, Naremaddepalli SSS: WO/2015033301 (2015).Google Scholar20 Sasikumar PGN, Ramachandra M, Naremaddepalli SSS: WO/2016/142833 (2016).Crossref, Google Scholar21 Lazorchak AS, Patterson T, Ding Y et al. Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer. Cancer Immunol. Res. 5, A36 (2017).Crossref, Google Scholar22 Sasikumar P, Sudarshan NS, Gowda N et al. Abstract 4861: oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy. Cancer Res. 76, 4861–4861 (2016).Crossref, Medline, Google Scholar23 Clinical Trials Database: NCT02812875. https://clinicaltrials.gov/ct2/show/study/NCT02812875.Google ScholarFiguresReferencesRelatedDetailsCited ByNear Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy31 January 2023 | International Journal of Molecular Sciences, Vol. 24, No. 3Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L127 June 2022 | BMC Chemistry, Vol. 16, No. 1Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy4 April 2022 | Frontiers in Immunology, Vol. 13SAR study of small molecule inhibitors of the programmed cell death‐1/programmed cell death‐ligand 1 interaction23 September 2021 | Chemical Biology & Drug Design, Vol. 98, No. 5Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits6 July 2021 | Cancers, Vol. 13, No. 14Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapyNeoplasia, Vol. 23, No. 3Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy22 October 2019 | Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules20 May 2019 | Molecules, Vol. 24, No. 10Immunotherapy… a pursuit race to tomorrow's medicinesAntonio Macchiarulo3 August 2017 | Future Medicinal Chemistry, Vol. 9, No. 12 Vol. 9, No. 12 Follow us on social media for the latest updates Metrics Downloaded 307 times History Published online 3 August 2017 Published in print August 2017 Information© 2017 Future Science LtdKeywordsantagonistcheckpoint inhibitorimmunomodulatorimmuno-oncologyimmunotherapyorally bioavailablePD-1 pathwayprotein–protein interactionsmall moleculeVISTAAcknowledgementsWe thank David Tuck and Tim Wyant (both from Curis, Inc.) for their comments on this manuscript.Financial & competing interests disclosureThe authors are full-time employees of Aurigene Discovery Technologies Limited, which holds multiple patents in the immuno-oncology space. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download